Conditioning Regimen in Elderly AML Patients Receiving Haplo-HSCT.

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Apr 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying two different treatment plans for elderly patients with acute myeloid leukemia (AML) who are receiving a special type of stem cell transplant called haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Researchers want to find out if one treatment plan, which includes specific medications (Bu/Flu/Cy/ATG), can help reduce the risk of serious complications compared to another plan (Bu/Cy/ATG). This is important because older patients often have a harder time with traditional chemotherapy, and improving their chances of survival with stem cell transplants is a key focus of this research.

To be eligible for this trial, patients need to be at least 55 years old, have AML in its first complete remission, and have a haploidentical donor available for the transplant. They also need to be willing to sign a consent form to participate. It’s important to note that patients with uncontrolled infections or certain other types of leukemia cannot join the study. If you or a loved one qualifies and decides to participate, you will be closely monitored and supported throughout the treatment process. This trial is not yet recruiting participants, but it aims to provide valuable information that could lead to better outcomes for elderly patients with AML in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - (a)Diagnosed with AML in first complete remission (CR1). (b)Age ≥55 years. (c)Availability of an haploidentical donor, first transplant, no matched sibling or unrelated donor.
• • (d)Willingness to provide written informed consent.
• Exclusion Criteria:
• • (a) Uncontrolled active infection. (b) Secondary AML. (c)Refusal to provide informed consent.